Evidence map›Paper›PMID 34985678›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2022

Cure and Long-Term Remission Strategies.

Luisa Mori, Susana T Valente

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Luisa MoriDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Susana T ValenteDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA. svalente@scripps.edu.

Funding

Mode of action of a new Tat HIV-1 inhibitorR01AI097012 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2012 to 2022
$7.5M
Host factors regulating HIV latency and reactivationR37AI165137 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2022 to 2026
$2.0M
Identification and characterization of chromatin regulators of HIV-1 latencyR33AI140439 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2021 to 2022
$1.8M
Host factors regulating HIV latency and reactivationR56AI165137 · NIAID · SCRIPPS FLORIDA · PI VALENTE, SUSANA T · 2021 to 2021
$463k
Host factors regulating HIV latency and reactivationR01AI165137 · NIAID · SCRIPPS FLORIDA · PI VALENTE, SUSANA T · 2022 to 2022
$0k
NIAID NIH HHS R01 AI097012NIAID NIH HHS R01 AI165137NIAID NIH HHS R33 AI140439NIAID NIH HHS R37 AI165137NIAID NIH HHS R56 AI165137
6 · The paper itself

Abstract

The majority of virally suppressed individuals will experience rapid viral rebound upon antiretroviral therapy (ART) interruption, providing a strong rationale for the development of cure strategies. Moreover, despite ART virological control, HIV infection is still associated with chronic immune activation, inflammation, comorbidities, and accelerated aging. These effects are believed to be due, in part, to low-grade persistent transcription and trickling production of viral proteins from the pool of latent proviruses constituting the viral reservoir. In recent years there has been an increasing interest in developing what has been termed a functional cure for HIV. This approach entails the long-term, durable control of viral expression in the absence of therapy, preventing disease progression and transmission, despite the presence of detectable integrated proviruses. One such strategy, the block-and-lock approach for a functional cure, proposes the epigenetic silencing of proviral expression, locking the virus in a profound latent state, from which reactivation is very unlikely. The proof-of-concept for this approach was demonstrated with the use of a specific small molecule targeting HIV transcription. Here we review the principles behind the block-and-lock approach and some of the additional strategies proposed to silence HIV expression.

Indexed as

HIV-1HIV InfectionsCD4-Positive T-LymphocytesHumansProvirusesVirus LatencyBlock-and-lockEpigenetic silencingHIV functional cureHIV transcriptionTat inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.